Death due to rare rhinocerebral mucormycosis infection: a case report

• Autorzy: Baral T. , Mugada V. , Kolakota R.K.
• Języki publikacji: EN

Abstrakty

EN

Background: Rhinocerebral mucormycosis is the most common form of mucormycosis in patients with diabetes mellitus; it is linked to poor prognosis, presenting most commonly in an acute setting, mimicking symptoms of sinusitis or periorbital cellulitis. The general survival rate in chronic cases is 83%, compared to 10–35% in acute. Aim of the study: To report a death due to rhinocerebral mucormycosis in a 45-year-old male patient. Case report: In this case report a 45-year-old male presented with acute rhinocerebral mucormycosis and was admitted in a state of unconsciousness with complaints of sudden onset weakness of right upper and lower limb, motor aphasia, right facial swelling, orbital swelling, and diminished distant vision. Upon primary diagnosis of stroke, treatment started immediately. However, past medical history from patient’s attendants revealed that the patient underwent a tooth extraction procedure 20 days prior, and had since developed redness of the right eye, diminished distant vision, and swelling of the right side of the face. Pus was drained, and reports revealed orbital cellulitis with an intracranial spread. By the time of admission to hospital, the patient had abnormal lab profiles (WBC, ESR, serum creatinine), acute kidney injury, with MRI revealing rhinocerebral mucormycosis. The patient developed septic shock and died during treatment. Conclusions: Acute mucormycosis carries a high mortality rate. Pleiotropic manifestations and organ dysfunction add to the further risk of mortality. Timely diagnosis and management may increase the chances of the survival rate of the patient.

• Wydawca: -
• Czasopismo: Medical Science Pulse
• Rocznik: 2019
• Tom: 13
• Numer: 4
• Opis fizyczny: p.40-43,fig.,ref.

Twórcy

autor

Baral T.

• Department of Pharmacy Practice, Vignan Institute of Pharmaceutical Technology Duvvada, AP, India

autor

Mugada V.

• Department of Pharmacy Practice, Vignan Institute of Pharmaceutical Technology Duvvada, AP, India

autor

Kolakota R.K.

• Department of Pharmacy Practice, Vignan Institute of Pharmaceutical Technology Duvvada, AP, India

Bibliografia

• 1. McSpadden R, Martin J, Mehrotra S, Thorpe E. Mucormycosis causing ludwig angina: a unique presentation. J Oral Maxillofac Surg 2017; 75(4): 759–762.
• 2. Yeo C, Kim J, Kwon S, Lee E, Lee M, Kim S, et al. Rhinocerebral mucormycosis after functional endoscopic sinus surgery. Medicine 2018; 97(51): e13290.
• 3. Kwon-Chung K. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis 2012; 54(suppl_1): S8–S15.
• 4. Roden M, Zaoutis T, Buchanan W, Knudsen T, Sarkisova T, Schaufele R, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41(5): 634–653.
• 5. Ibrahim A, Spellberg B, Edwards J. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 2008; 21(6): 620–625.
• 6. Mulki R, Masab M, Eiger G, Perloff S. Lethargy and vision loss: successful management of rhinocerebral mucormycosis. BMJ Case Reports 2016; bcr2016215855.
• 7. Sahota R, Gambhir R, Anand, Dixit A. Rhinocerebral mucormycosis: report of a rare case. Ethiop J Health Sci 2017; 27(1): 85.
• 8. Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18(3): 556–569.
• 9. Reddy S, Rakesh N, Chauhan P, Sharma S. Rhinocerebral mucormycosis among diabetic patients: an emerging trend. Mycopathologia 2015; 180(5–6): 389–396.
• 10. Hosseini S, Borghei P. Rhinocerebral mucormycosis: pathways of spread. Eur Arch Otorhinolaryngol 2005; 262(11): 932–938.
• 11. Kolekar J. Rhinocerebral mucormycosis: a retrospective study. Indian J Otolaryngol Head Neck Surg 2015; 67(1): 93–96.
• 12. Dimaka K, Mallis A, Naxakis S, Marangos M, Papadas T, Stathas T, et al. Chronic rhinocerebral mucormycosis: a rare case report and review of the literature. Mycoses 2014; 57(11): 699–702.
• 13. Dellinger R, Levy M, Carlet J, Bion J, Parker M, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36(1): 296–327.
• 14. Reed C, Bryant R, Ibrahim A, Edwards, Jr. J, Filler S, Goldberg R, et al. Combination polyene‐caspofungin treatment of rhino‐orbital‐cerebral mucormycosis. Clin Infect Dis 2008; 47(3): 364–371.
• 15. Spellberg B, Walsh T, Kontoyiannis D, Edwards Jr J, Ibrahim A. Recent advances in the management of mucormycosis: from Bench to Bedside. Clin Infect Dis 2009; 48(12): 1743–1751.
• 16. Riley T, Muzny C, Swiatlo E, Legendre D. Breaking the mold: a review of mucormycosis and current pharmacological treatment options. Ann Pharmacother 2016; 50(9): 747–757.
• 17. Baugh WP. Rhinocerebral mucormycosis treatment & management: approach considerations, amphotericin B, other antifungal therapies [online] 2018 [cit. 13.12.2019]. Available from URL: https://emedicine.medscape.com/article/227586-treatment#d11.

Identyfikatory

DOI

10.5604/01.3001.0013.7444